Aptabio Therapeutics Inc.
Develops drugs for fibrosis, inflammation, and cancer using NOX inhibitor & CAF modulation tech.
293780 | KO
Overview
Corporate Details
- ISIN(s):
- N/A
- LEI:
- Country:
- South Korea
- Address:
- 경기도 용인시 기흥구 흥덕1로 13 타워동 에이504호(영덕동, 흥덕아이티밸리), 용인시
- Website:
- https://aptabio.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Aptabio Therapeutics Inc. is a biopharmaceutical company specializing in the development of first-in-class drugs for intractable diseases. The company leverages two proprietary platform technologies to address high unmet medical needs. Its primary platform develops selective inhibitors of the NOX family of enzymes to control oxidative stress, targeting inflammation and fibrosis-related conditions like diabetic complications, vascular diseases, and neurodegenerative disorders. A second platform focuses on modulating Cancer-Associated Fibroblasts (CAF) to enhance the efficacy of immune-oncology therapies and overcome treatment resistance in hard-to-treat cancers.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-08-28 00:00 |
Regulatory News Service
[기재정정]투자판단관련주요경영사항(임상시험계획승인신청) (ABF101의 미국 FDA 제1상 임상시험계획 승인신청(IND…
|
Korean | 13.7 KB | ||
| 2025-08-14 00:00 |
Interim Report
반기보고서 (2025.06)
|
Korean | 1.4 MB | ||
| 2025-07-28 00:00 |
Legal Proceedings Report
투자판단관련주요경영사항(임상시험계획승인신청) (ABF101의 미국 FDA 제1상 임상시험계획 승인신청(IND))
|
Korean | 8.4 KB | ||
| 2025-07-10 00:00 |
Report Publication Announcement
기업설명회(IR)개최
|
Korean | 6.9 KB | ||
| 2025-07-07 00:00 |
Report Publication Announcement
기업설명회(IR)개최
|
Korean | 6.9 KB | ||
| 2025-06-18 00:00 |
Regulatory News Service
기타경영사항(자율공시) ([국책과제 선정] 국가신약개발사업단(KDDF)(당뇨병성 신증 환자에서 panNOX 저해제 …
|
Korean | 6.8 KB | ||
| 2025-06-18 00:00 |
Regulatory News Service
투자판단관련주요경영사항(임상시험계획승인신청등결정) (APX343A의 제1상 임상시험계획(IND) 승인)
|
Korean | 9.9 KB | ||
| 2025-06-04 00:00 |
M&A Activity
합병등종료보고서(합병)
|
Korean | 17.4 KB | ||
| 2025-05-28 00:00 |
Major Shareholding Notification
주식등의대량보유상황보고서(약식)
|
Korean | 66.4 KB | ||
| 2025-05-26 00:00 |
Share Issue/Capital Change
전환가액의조정
|
Korean | 18.9 KB | ||
| 2025-05-19 00:00 |
Report Publication Announcement
기업설명회(IR)개최
|
Korean | 6.9 KB | ||
| 2025-05-15 00:00 |
Quarterly Report
분기보고서 (2025.03)
|
Korean | 1.1 MB | ||
| 2025-05-12 00:00 |
Share Issue/Capital Change
주요사항보고서(제3자의전환사채매수선택권행사)
|
Korean | 20.5 KB | ||
| 2025-04-02 00:00 |
Report Publication Announcement
기업설명회(IR)개최
|
Korean | 6.9 KB | ||
| 2025-04-01 00:00 |
M&A Activity
주요사항보고서(회사합병결정)
|
Korean | 62.9 KB |
Automate Your Workflow. Get a real-time feed of all Aptabio Therapeutics Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for Aptabio Therapeutics Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
